We still haven't seen any safety data. So that makes me a bit cautious. If it's clean, then I think the stock still has quite a ways to go, although of course this is already a partnered asset. There are substantial milestones in their agreement, and if you back those out the market cap isn't excessive at all if the drug becomes the SOC in prostate.
From all the data I have looked at, 1.5 billion is dirt cheap. does not appear to be any safety issues at the current dose. with zytiga needing the steriod, mdv3100 looks even better.
the early lab data comparing it to Casodex (Bicalutamide) looks great, prevail study should do well. early breast cancer data looks good also.
I thought we might see some insider buying and what do ya know )) http://openinsider.com/MDVN and that is a guy that owns 600K already.
the stand still agreement with astellas ends at the launch -I think astellas will offer them around 4 billion after launch. that would be cheap if prevail looks like I think it will -and dirt cheap considering the breast cancer data.
I don't like chasing cancer stocks after they double, but I think we have a blockbuster here. just a bit more info.
the last time I chased a cancer stock after it doubled was mederex )) I don't do it often, but this one is appears exceptional.
they will get a check for just over 200 million after approval in late 2012. they should end 2012 with about 300 million in cash.
Market Data 
Markets 
AI
